Lorlanib 100 Mg (Lorlatinib) Tablets

Lorlanib-100 (Lorlatinib 100 mg) is a targeted anticancer medicine used for the treatment of specific types of non-small cell lung cancer (NSCLC) associated with ALK or ROS1 genetic alterations. It works by blocking abnormal proteins that promote cancer cell growth and spread.

Therapeutic Effects:

• Helps slow or stop the growth of cancer cells
• Supports the management of advanced or metastatic NSCLC
• Targets ALK-positive and ROS1-positive lung cancer
• May help reduce disease progression
• Designed to act on specific genetic mutations driving tumor growth 

Active Ingredient:

• Lorlatinib USP 100 mg

Composition:
Each film-coated tablet contains:

• Lorlatinib USP equivalent to 100 mg Lorlatinib

Pharmaceutical Form:

• Film-Coated Tablet
• Oral Administration

Recommended Adult Dose:

• One tablet (100 mg) taken orally once daily, or as directed by a qualified healthcare professional.

Administration Guidelines:

• Swallow the tablet whole with water.
• Can be taken with or without food.
• Take at approximately the same time each day for consistent therapeutic benefit.
• Do not crush, chew, or split the tablet unless advised by a healthcare provider.

Missed Dose:

• If a dose is missed, take it as soon as remembered unless the next scheduled dose is due within a short period.
• Do not take two doses at the same time to make up for a missed dose.

Important Note:

• Treatment duration and dose adjustments should be determined by an oncology specialist based on clinical response, tolerability, and individual patient needs.
• Regular medical monitoring may be required throughout treatment.